- Home
- FCAP vs WHWK Comparison
FCAP vs WHWK Comparison
Compare FCAP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | WHWK |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.1M | 197.2M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | FCAP | WHWK |
|---|---|---|
| Price | $55.26 | $4.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 1.9K | ★ 200.0K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 36.97 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $7,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.08 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $33.88 | $1.56 |
| 52 Week High | $71.00 | $4.40 |
Technical Indicators
Market Signals| Indicator | FCAP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 59.02 |
| Support Level | $50.24 | $3.24 |
| Resistance Level | $56.40 | $4.40 |
| Average True Range (ATR) | 0.89 | 0.24 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 79.57 | 62.70 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.